Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weight-loss surgery prep trial pulled before it even started

NCT ID NCT05710263

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if blocking blood vessels to part of the stomach (bariatric embolization) could help super obese patients lose weight before sleeve gastrectomy surgery, potentially lowering surgical risks. It planned to enroll patients with a BMI over 50 and at least three risk factors. However, the trial was withdrawn before any participants were enrolled, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bariatric embolization (blocking blood vessels to part of the stomach)
What this could lead to
If it had worked, this could have pointed toward a safer way to help super obese patients lose weight before surgery, reducing surgical risks.
What could go wrong
The trial was withdrawn before any patients enrolled, so no results exist. The approach is experimental and carries risks like bleeding or infection from the embolization procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Started

Jan 2023

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing, able and mentally competent to provide written informed consent. * Body mass index (BMI) \>50kg/m². * 3 risk factors (De Maria et al) among: hypertension, male gender, age\>45, risk of pulmonary embolism * Vascular anatomy (including celiac, hepatic, and gastric arteries) that in the opinion of the interventional radiologist amenable to Bariatric Embolization, as assessed on 3D CT angiography. * Adequate hematological, hepatic and renal function as follows: Hematological Neutrophils \> 1.5 x 109/L Platelets \> 100 x 109/L INR \<1.5 Hepatic Bilirubin ≤ 2.0 mg/dL Albumin ≥ 2.5 g/L Renal Estimated GFR \> 60ml/min.1.73m2 * Aged 18 years or older. * Patient who is going to be operated by sleeve gastrectomy Exclusion Criteria: * Prior history of gastric pancreatic, hepatic, and/or splenic surgery * Prior radiation to the upper abdomen * Prior embolization to the stomach, spleen or liver * Portal venous hypertension * Prior or current history of peptic ulcer disease * Significant risk factors for peptic ulcer disease including daily NSAID use and smoking. * Active H. Pylori infection * Weight greater than 240 kg * Known aortic pathology such as aneurysm or dissection renal insufficiency as evidenced by an estimated glomerular filtration rate of \< 60 milliliters per minute * Major comorbidity such as cancer, significant cardiovascular disease, diabetes, or peripheral arterial disease. Pregnancy * ASA Class 4 or 5 (very high risk surgical candidates: class 4= incapacitating disease that is a constant threat to life) at the time of screening for enrollment into the study will be excluded from participation. This exclusion criterion exists because of the possibility that surgical intervention will be needed if the study intervention subsequently leads to severe adverse effects. * History of Inflammatory Bowel Disease * Cirrhosis * Known history of allergy to iodinated contrast media * Contraindications to use Embosphere (ex:known allergy to gelatin ..)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bariatric surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.